Skip to content

Identification of KL29 type acinetobacter baumannii phage of obolenskvirus subfamily and tail-associated depolymerase activity

Aug 2026 · Archives of Virology · Vol 171 · 0 citations · 41 references
Medicine

TL;DR

This study characterizes Dp49, a newly discovered bacteriophage-derived depolymerase exhibiting potent enzymatic activity against bacterial exopolysaccharides and anti-biofilm activity, which demonstrates therapeutic potential by enhancing serum-mediated bactericidal activity and anti-biofilm activity.

View source

Similar papers

Open access Sep 2026

YtnP lactonase from Bacillus licheniformis T2 mitigates virulence and biofilm formation in carbapenem-resistant Acinetobacter baumannii via quorum sensing quenching

Carbapenem-resistant Acinetobacter baumannii (CRAB) has become a predominant nosocomial pathogen worldwide, with biofilm formation and quorum sensing (QS) primarily responsible for its high antimicrobial tolerance and clinical refractory infections. Targeting bacterial virulence rather than conventional bacteri...

Bin Liu, Cai-Hua Li, Yi-Zhen Zhu et al. · 0 citations
Open access Jan 2026

Characterization and Therapeutic Potential of a Novel Lytic Bacteriophage vB_Kp_H122 Targeting Multidrug‐Resistant Hypervirulent Klebsiella pneumoniae of K57 Capsular Type

It is suggested that vB_Kp_H122 may have potential as an antibacterial candidate against K57 MDR‐hvKP isolates, a novel lytic phage that specifically targets K57 capsular‐type MDR‐hvKP.

Cuilong Fan, Qiu Xu, S. Schwarz et al. · 0 citations
Open access Aug 2026

Deciphering the genomic landscape of novel Acinetobacter non-baumannii lineages causing neonatal septicemia: carbapenem resistance and virulence

Background Acinetobacter non-baumannii (Anb) species are reported worldwide to cause infections in both adults and neonates, although less frequently than Acinetobacter baumannii. However, limited information is available on their genomic diversity, resistance mechanisms, and virulence potential. This study investigate...

Subhasree Roy, Daichi Morita, Tanusree Das et al. · 0 citations
Open access Sep 2026

PiuA promoter mutations confer cefiderocol resistance in Acinetobacter baumannii: from in vitro evolution to global genomic screening

Introduction Carbapenem-resistant Acinetobacter baumannii (CRAB) poses a global health threat due to limited therapeutic options. Cefiderocol, a novel siderophore-conjugated cephalosporin, demonstrates potent in vitro activity against a variety of Gram-negative bacteria, including CRAB. However, cefiderocol's recent in...

Xiao-Chen Liu, Qing-Ye Xu, Jin-Tao He et al. · 0 citations
Review Open access Sep 2026

Synthetic aminoglycoside derivatives as anti-virulence agents against multidrug-resistant Acinetobacter baumannii

Acinetobacter baumannii presents a severe clinical challenge in critical care due to its rapid acquisition of drug resistance and its ability to form dense biofilms on medical equipment. While traditional antibiotic research focuses almost exclusively on essential bacterial viability targets, targeting virulence factor...

N. S. Faris, Omar Hadieh, Mohammad M. Hadieh · 0 citations
Open access Sep 2026

Environmental isolation and in vitro characterisation of bacteriophages active against multidrug-resistant Acinetobacter baumannii.

Background The increasing prevalence of antimicrobial resistance (AMR) has created an urgent need for alternative therapeutic strategies. Acinetobacter baumannii, a major cause of hospital-acquired infections, has been classified by the World Health Organization as a critical priority pathogen due to its high levels of...

Souradeep Chowdhury, N. Rathor, M. Soneja et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.